Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Meta-Analysis: No Benefit For Cardiac Resynch In Patients With Narrow QRS Interval

This article was originally published in The Gray Sheet

Executive Summary

Cardiac resynchronization therapy may not benefit up to 40% of heart failure patients who currently receive CRT devices and whose “QRS duration” on an electrocardiogram is below a certain threshold, according to a meta-analysis published June 13.

You may also be interested in...

Cardiac Resynchronization Is Inappropriate For Patients With Short QRS, Study Confirms

The trial shows that cardiac-resynchronization therapy does not reduce mortality or hospitalizations in heart failure patients with a QRS duration shorter than 130 milliseconds on an electrocardiogram. The finding essentially affirms current guidelines, but it does not support off-label practice by some cardiologists who had hoped CRT could be useful in a broader patient population.

ICD Scrutiny: Study Quantifies Significant Off-Guideline Implant Activity

The implantable defibrillator sector took another potential hit last week with findings that more than 20% of patients treated with the devices for primary prevention of sudden cardiac death should not receive them under current guidelines.

FDA Panel Endorses Expanded Approval For Boston Scientific CRT-Ds

Boston Scientific's cardiac resynchronization therapy defibrillators (CRT-Ds) should be approved for use in some healthier heart failure patients, though not quite as many as the company initially proposed, an FDA advisory panel said March 18

Related Content




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts